富祥药业：通过美国FDA现场检查

Core Insights - The company successfully passed a cGMP inspection by the FDA from August 11 to August 14, 2025, covering various quality and management systems [1] - This marks the third successful cGMP inspection by the FDA, indicating the company's quality systems are aligned with international standards [1] - The successful inspection qualifies the company to continuously provide commercial intermediates and active pharmaceutical ingredients for the U.S. and global markets [1]